MET inhibition overcomes radiation resistance of glioblastoma stem-like cells

EMBO Molecular Medicine

Volumn 8, Issue 5, 2016, Pages 550-568

  De Bacco, Francesca ^a   D'Ambrosio, Antonio ^a,b   Casanova, Elena ^a   Orzan, Francesca ^a   Neggia, Roberta ^a   Albano, Raffaella ^a   Verginelli, Federica ^a   Cominelli, Manuela ^c   Poliani, Pietro L ^c   Luraghi, Paolo ^a   Reato, Gigliola ^a,b   Pellegatta, Serena ^d   Finocchiaro, Gaetano ^d   Perera, Timothy ^e   Garibaldi, Elisabetta ^a   Gabriele, Pietro ^a   Comoglio, Paolo M ^a,b   Boccaccio, Carla ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e Octimet Oncology Ltd   (United Kingdom)

Author keywords

Glioblastoma; Glioblastoma stem like cells; MET oncogene; Radiosensitization; Radiotherapy

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; ATM PROTEIN; AURORA A KINASE; CRIZOTINIB; JNJ 38877605; MET RECEPTOR KINASE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN P21; UNCLASSIFIED DRUG; ATM PROTEIN, HUMAN; AURKA PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MET PROTEIN, HUMAN; ONCOPROTEIN; SCATTER FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ERADICATION THERAPY; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA STEM LIKE CELL; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; XENOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; METABOLISM; PHYSIOLOGY; RADIATION RESPONSE; STEM CELL; XENOGRAFT;

ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; AURORA KINASE A; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA REPAIR; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; MICE; ONCOGENE PROTEIN V-AKT; PROTO-ONCOGENE PROTEINS C-MET; STEM CELLS;

EID: 84962699438     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201505890     Document Type: Article

References (46)

1. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414
2. Ahmed SU, Carruthers R, Gilmour L, Yildirim S, Watts C, Chalmers AJ (2015) Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Res 75: 4416-4428
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760
4. Baralis E, Bertotti A, Fiori A, Grand A (2012) LAS: a software platform to support oncological data management. J Med Syst 36(Suppl. 1): S81-S90
5. Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8: 545-554
6. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD et al (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24: 331-346
7. Blanpain C, Mohrin M, Sotiropoulou PA, Passegue E (2011) DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8: 16-29
8. Boccaccio C, Comoglio PM (2014) MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. Curr Opin Cell Biol 31: 98-105
9. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH et al (2013) The somatic genomic landscape of glioblastoma. Cell 155: 462-477
10. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82
11. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404
12. Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, Rich JN, Bao S (2011) L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J 30: 800-813
13. De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C (2011) Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 103: 645-661
14. De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P et al (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 72: 4537-4550
15. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783
16. Ene CI, Holland EC (2015) Personalized medicine for gliomas. Surg Neurol Int 6: S89-S95
17. Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, West SC (2005) CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434: 598-604
18. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De VS, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021
19. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: l1
20. van Gent DC, Hoeijmakers JH, Kanaar R (2001) Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2: 196-206
21. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC (2008) PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22: 436-448
22. Joo KM, Jin J, Kim E, Ho KK, Kim Y, Gu KB, Kang YJ, Lathia JD, Cheong KH, Song PH et al (2012) MET signaling regulates glioblastoma stem cells. Cancer Res 72: 3828-3838
23. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF (1997) Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57: 5391-5398
24. Krause M, Yaromina A, Eicheler W, Koch U, Baumann M (2011) Cancer stem cells: targets and potential biomarkers for radiotherapy. Clin Cancer Res 17: 7224-7229
25. Kunkel P, Muller S, Schirmacher P, Stavrou D, Fillbrandt R, Westphal M, Lamszus K (2001) Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro Oncol 3: 82-88
26. Lal B, Xia S, Abounader R, Laterra J (2005) Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11: 4479-4486
27. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cazares H, Eberhart CG et al (2011) c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA 108: 9951-9956
28. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6: 61-73
29. Olive PL (2004) Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol 75: 355-373
30. Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De SR, Galluzzo M, Carminati P, Comoglio PM, Michieli P, Vigna E (2010) Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 285: 36149-36157
31. Pajonk F, Vlashi E, McBride WH (2010) Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28: 639-648
32. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140: 62-73
33. Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9: 314-326
34. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L et al (2006a) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173
35. Phillips TM, McBride WH, Pajonk F (2006b) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785
36. Richichi C, Brescia P, Alberizzi V, Fornasari L, Pelicci G (2013) Marker-independent method for isolating slow-dividing cancer stem cells in human glioblastoma. Neoplasia 15: 840-847
37. Scheel C, Weinberg RA (2012) Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin Cancer Biol 22: 396-403
38. Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14: 197-210
39. Squatrito M, Holland EC (2011) DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res 71: 5945-5949
40. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466
41. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110
42. Vigna E, Comoglio PM (2015) Targeting the oncogenic Met receptor by antibodies and gene therapy. Oncogene 34: 1883-1889
43. Vlashi E, Pajonk F (2014) Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol 31: 28-35
44. Walter AO, Seghezzi W, Korver W, Sheung J, Lees E (2000) The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 19: 4906-4916
45. Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y et al (2012) Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci USA 109: 570-575
46. Yang C, Tang X, Guo X, Niikura Y, Kitagawa K, Cui K, Wong ST, Fu L, Xu B (2011) Aurora-B mediated ATM serine 1403 phosphorylation is required for mitotic ATM activation and the spindle checkpoint. Mol Cell 44: 597-608